Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)

Next Previous
Trial Profile

Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camonsertib (Primary) ; Gemcitabine (Primary) ; Talazoparib (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Carcinoma; Colorectal cancer; Ductal carcinoma; Gynaecological cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms TRESR
  • Sponsors Repare Therapeutics

Most Recent Events

  • 31 Jan 2025 Status changed from recruiting to active, no longer recruiting.
  • 24 Sep 2024 This trial has been completed in Denmark according to European Clinical Trials Database record.
  • 13 Sep 2024 According to a Repare Therapeutics media release, the Company will share new data from Module 1 of this trial during an oral presentation on September 14 at the European Society for Medical Oncology Congress (ESMO), held in Barcelona, Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top